Leerink Partners Initiates Coverage On Quince Therapeutics with Outperform Rating, Announces Price Target of $4
Cantor Fitzgerald Initiates Coverage On Quince Therapeutics with Overweight Rating, Announces Price Target of $4
Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcript
Quince Therapeutics, Inc. (QNCX) OrphAI Therapeutics Inc - M&A Call - Slideshow
Quince Therapeutics, Inc. (QNCX) M&A Call Prepared Remarks Transcript
Quince Therapeutics Announces Acquisition Of Orphai Therapeutics In Stock-For-Stock Deal; Quince Enters Concurrent Private Placement Agreement To Raise Up To $187M
Quince Therapeutics Reports Phase 2a Data For LAM-001 In Pulmonary Hypertension-Associated ILD, Demonstrated Clinically Meaningful Improvement In Multiple Assessments Of Lung Function, Including Improvement In 6MWD Of 67.4 Meters And PVR Reduction Of 33.9% At 24 Weeks; Phase 2b Trial In PH-ILD To Initiate In Mid-2026, With Topline Data Anticipated In Q1 2028
Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
Quince Therapeutics shares are trading higher after the company announced a settlement of its outstanding obligations under a loan from the European Investment Bank for a payment of $5.5 million.
Quince Therapeutics Settles $5.5M Loan Under Its Obligations From European Investment Bank
BC-Most Active Stocks
What Does the Market Think About Quince Therapeutics Inc?
What Sparked Quince Therapeutics (QNCX) Stock To Rise 53% After Hours
Quince Therapeutics Stock Plunges As Filing Shows Reverse Merger Plans, Bankruptcy Risks
On Wednesday, there are stocks with unusual volume. Let's take a look.
Quince Therapeutics Stock Extends Rally On Strategic Review
Quince Therapeutics, Spotify, S&P Global, Intel And Datadog: Why These 5 Stocks Are On Investors' Radars Today
Quince Therapeutics shares are trading higher after the company announced it is exploring strategic alternatives.
Quince Therapeutics Stock Explodes 300% On Strategic Review
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.
